Fresenius Kabi has acquired Ivenix, Inc. to enhance its infusion therapy offerings in the U.S. market.

Target Company Overview

Fresenius Kabi has successfully acquired Ivenix, Inc., a company specialized in infusion therapy. The transaction, initially announced on March 31, 2022, marks a significant step in Fresenius Kabi's expansion strategy in the U.S. market. With Ivenix's innovative infusion therapy platform, Fresenius Kabi enhances its portfolio, embedding cutting-edge technology into its product offerings.

Ivenix is known for its advanced infusion systems that enable improved hospital connectivity and interoperability. This acquisition allows Fresenius Kabi to leverage Ivenix's expertise and technology, thereby enhancing its capabilities in intravenous therapies.

Industry Overview in the U.S.

The U.S. infusion therapy market is experiencing substantial growth, driven by the rising prevalence of chronic diseases and the demand for advanced treatment options. Innovative infusion devices are becoming critical